ScholarIQanswers from OpenAlex & ORCID
James Larkin
ResearcherPublications, citations & collaboration network
James Larkin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does James Larkin have?
ScholarIQindexed works
James Larkin has 1,398 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does James Larkin have?
ScholarIQcitation count
James Larkin has 133,749 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of James Larkin?
ScholarIQh-index
James Larkin has an h-index of 130 in OpenAlex.
What is the i10-index of James Larkin?
ScholarIQi10-index
James Larkin has an i10-index of 562 in OpenAlex.
What is the ORCID of James Larkin?
ScholarIQorcid
The ORCID for James Larkin is on the source record.
What is the OpenAlex record for James Larkin?
ScholarIQopenalex
The OpenAlex for James Larkin is on the source record.
What are the most-cited papers on James Larkin?
ScholarIQmost cited works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Négrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, B. Yа. Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K. Choueiri
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina V. Long, Reinhard Dummer, Omid Hamid, Thomas F. Gajewski, Christian Caglevic, Stéphane Dalle, Ana Arance, Matteo S. Carlino, Jean‐Jacques Grob, Tae Min Kim, Lev Demidov, Caroline Robert, James Larkin, James R. Anderson, Janet Maleski, Mark M. Jones, Scott J. Diede, Tara C. Mitchell